Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

BACKGROUND: Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients re...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Rheumatol
Päätekijät: Biran, Noa, Ip, Andrew, Ahn, Jaeil, Go, Ronaldo C, Wang, Shuqi, Mathura, Shivam, Sinclaire, Brittany A, Bednarz, Urszula, Marafelias, Michael, Hansen, Eric, Siegel, David S, Goy, Andre H, Pecora, Andrew L, Sawczuk, Ihor S, Koniaris, Lauren S, Simwenyi, Micky, Varga, Daniel W, Tank, Lisa K, Stein, Aaron A, Allusson, Valerie, Lin, George S, Oser, William F, Tuma, Roman A, Reichman, Joseph, Brusco, Louis, Carpenter, Kim L, Costanzo, Eric J, Vivona, Vincent, Goldberg, Stuart L
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier Ltd. 2020
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7428303/
https://ncbi.nlm.nih.gov/pubmed/32838323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2665-9913(20)30277-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia